Navigation Links
Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago
Date:6/12/2009

DOYLESTOWN, Pa., June 12 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com, today announced the resignation of Guy J. Quigley as Chairman, President and Chief Executive Officer of the Company. The resignation is effective immediately, following a proxy contest which culminated on May 20 at the Company's annual meeting which favored dissident shareholder Ted Karkus and his proposed slate of directors. The Company has accepted the resignation of Charles A. Phillips, COO of The Quigley Corporation and Wendy D. Quigley, Accounting Operations Manager. Mr. Phillips and Ms. Quigley have been with the Company since its inception in 1989.

Guy J. Quigley founded The Quigley Corporation at his dining room table, self funding the company for its first six years without a salary. Mr. Quigley took the Company public in 1991 and established the COLD-EEZE(R) brand in 1992.

Under his leadership, COLD-EEZE has become the number three selling cough cold lozenge and the number one pharmacist recommended zinc cold treatment.

In 2001, he established Quigley Pharma Inc., with a focus on the research and development of naturally-derived compounds. As part of his strategic plan to develop the pharma operation, he oversaw its self-funding with the revenue generated by COLD-EEZE. Under his leadership, $28 million has been self-funded in Quigley Pharma since inception, without any dilution to shareholders.

Since that time, Quigley Pharma has brought two drug development programs to the position where they can begin to offer stockholders value. Findings of significantly improved nerve conduction in patients with Diabetic Peripheral Neuropathy demonstrate that the QR-333 compound has potential to generate value for stockholders. Conversations with four potential veterinary drug development partners regarding the QR-448 antiviral development program are ongoing and demonstrate another source of potential value for stockholders

Guy J. Quigley, Chairman, President and Chief Executive Officer stated, "Despite everything that has been said and done during the course of this proxy contest, my goal has been and continues to build stockholder value. I am very proud of our work over the past 20 years. COLD-EEZE is a highly-respected product and well-established household name and Quigley Pharma has several compounds which have reached a point of value inflection."

"The new Board is now tasked with the responsibility of rewarding stockholders who have patiently held their shares over the years, and refrain from rewarding only those who they bring to the table at the 11th hour to profit from the years of work and patience on behalf of the resigning Board, and the stockholders of The Quigley Corporation. We remain hopeful that the newly elected Board will convert value from the table that has been set for them. To ensure the Company continues to function in the wake of the new Board's unknown plans, I have asked our CFO, Gerard Gleeson to remain in charge until further announcements by the new Board of Directors."

About The Quigley Corporation

The Quigley Corporation (NASDAQ: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfilling other contract manufacturing opportunities and Quigley Pharma Inc. (http://www.QuigleyPharma.com), which conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

    CONTACT:        Media                        Investor Relations
                    Karen Pineman                Carl Hymans
                    G.S. Schwartz & Co.          G.S. Schwartz & Co.
                    212.725.4500                 212.725.4500
                    kpineman@schwartz.com        carlh@schwartz.com


'/>"/>
SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division
2. The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future
3. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
4. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
5. Helix BioPharma Chairman resigns
6. NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Companys Audit Committee
7. Senesco Technologies, Inc. Announces the Appointment of Dr. Harlan W. Waksal, M.D. as Chairman of the Board of Directors and the Addition of Mr. Warren J. Isabelle, CFA to its Board of Directors
8. Matt Bars, a Global Expert in Smoking Cessation, Joins Next Safety as Chairman
9. Vasogen Appoints Dr. Eldon Smith Chairman
10. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
11. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... , May 19, 2016  AdvancedFlow Systems ... Inc. (AGI), based out of Maple ... Biogas Ltd. to its existing portfolio of contract ... agreement. AFS along with its sister companies Surround ... a vertically integrated industrial group that specializes in ...
(Date:5/19/2016)... , May 19, 2016 ... and (OTC PINK: RGBPP) announced today initiation of ... first cord blood based cancer immunotherapeutic product leveraging ... application, Regen described a generation of cord blood ... by gene silencing.  The product in development will ...
(Date:5/18/2016)... ... May 18, 2016 , ... Shimadzu Scientific ... The University of Toledo. This two-day camp will take place annually starting June ... field of pharmaceutical sciences in preparation for a university academic program. , ...
(Date:5/18/2016)... ... May 18, 2016 , ... Every day, ... result of asthma complications.* Costing more than $56 billion in direct costs annually, ... , “For too many, the suffering associated with uncontrolled asthma can be overwhelmingly ...
Breaking Biology Technology:
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
Breaking Biology News(10 mins):